SHUSTIK, J. Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor. Canadian Hematology Today, Toronto, Canada, v. 4, n. 3, p. 24–35, 2025. DOI: 10.58931/cht.2025.4379. Disponível em: https://canadianhematologytoday.com/article/view/4-3-Shustik. Acesso em: 12 dec. 2025.